The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. Authors marked with an asterisk (*) are participants in ASCO’s Disclosure Management System Pilot; their disclosure is not limited to subject matter under consideration in this article and includes payments to themselves, an immediate family member (I), and/or their institutions (Inst). For information on the pilot program, or to provide feedback, please visit coipilot.asco.org. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A statewide evaluation of adjuvant chemotherapy for stage III colon cancer.
N. J. Petrelli
Consultant or Advisory Role - Genentech
* S. S. Grubbs
No relevant relationships to disclose
J. E. Spellman
No relevant relationships to disclose
C. L. English
No relevant relationships to disclose
A. Shevock
No relevant relationships to disclose
K. Nunley
No relevant relationships to disclose